SPEAKER BIOGRAPHIES: Balu Balasubramanian, Ph.D., Director, Discovery Chemistry, Bristol-Myers Squibb Co. Speaker bio to be submitted. Andrew Branca, SVP, Strategic Research, Cambridge Healthtech Associates Andrew Branca has ten years' experience in providing strategic business analysis and consulting to pharmaceutical, biotechnology, and drug discovery technology companies. He is a highly sought consultant to major pharmaceutical companies and a frequent speaker at industry events. Prior to joining Cambridge Healthtech, Andrew was Director of the Breakthrough Technologies service at Decision Resources. In this role, he evaluated the strategic and scientific promise and the market potential of emerging drug discovery technologies. Andrew received his graduate education in Molecular Biology at Harvard University. He also holds a BA from Binghamton University and a JD from the Hofstra University School of Law. Michael Chen, President, TCM Group, Inc., former Associate Director, Biostatistics and Data Management, Wyeth Michael Chen, Ph.D, is President of TCM Groups, Inc, a consulting company. He has advised pharmaceutical and biotechnology firms for the past 5 years on issues related to china strategy and execution. His main areas of expertise are in regulatory, clinical trials, and business development, including joint venture and licensing. He has assisted international biopharma companies conducted clinical studies and successfully assisted clients to introduce 3 products into china. Before founding of TCM, he was an associate director of biostatistics and data management at Wyeth. Samantha Du, Ph.D., Managing Director, Hutchison MediPharma Ltd., Chief Scientific Officer & Executive Vice President, Hutchison China Meditech Limited Dr. Du is the Managing Director of Hutchison Medipharma Limited; Chief Scientific Officer and Executive Vice President of Hutchison Chi-Med, a publicly traded company in London. Samantha joined Hutchison in 2001 and has since led and involved all aspects of R&D and investment activities. In 2003, she founded Hutchison Medipharma Limited, a R&D based company focusing on oncology and autoimmune diseases, in Shanghai, China. The company has since grew to over 100 employees with cutting edge technology platforms and a rich portfolio of drug candidates at various stages of development including one in US phase II trial for IBD diseases and one in US phase I/II trials for radiosensitizer. Prior to Hutchison, she was at Pfizer’s global strategic operation division in US in charge of Licensing and related MPA activities for metabolic diseases. She started her research career at Pfizer’s Global R&D in Connecticut and led teams that delivered multiple INDs and NDAs in several therapeutic areas. Dr. Du served on FDA sponsored working committees and is currently an active adviser on healthcare issues for various government agencies in China. Mark Engel, Chairman, Excel PharmaStudies Mark is the co-founder of Excel PharmaStudies, the largest full service clinical research organization in China with operations in Beijing, Shanghai, Guangzhou, Chengdu, Chongqing, Nanjing and Shenyang. In the last several years, Excel has been involved in about 125 phase I to IV trials in 29 cities at about 130 hospitals, and covering around 25,000 patients. The trials have been for either purposes of local registrations or for international approvals. Excel has strong medical, regulatory and data management teams. Our clients include many of the top 60 international pharmaceutical companies and many of the leading Chinese pharmaceutical companies. Mark is also the co-founder of several other medically related companies in China: (1) Haoyisheng, the leading health care information, education and software company in China with about 350 employees; and (2) The Tiger Group, including Tiger Medical Products, Tiger Health Care Group, Tiger Specialty Sourcing and TPNT. Mark lives in Shanghai with his wife and two sons. In his spare time Mark likes to play bad golf. Rajiv Gulati, Director, China-India Strategy, Corporate Strategic Planning, Eli Lilly & Co. Rajiv Gulati has recently moved to company headquarters in Indianapolis as Director, China-India Strategy, Corporate Strategy Group. Previously, he had been Chairman and Managing Director, Eli Lilly and Company (India). Gulati s career began with the Pharmaceutical Industry in 1982. He has been associated with the Indian affiliate since its inception in 1992, and has played a key role in the formation, and expansion of this affiliate. Gulati, a native of Ambala, India, joined Lilly from Ranbaxy Laboratories in 1992 on the formation of the companies' joint venture. Gulati held the position of General Manager, of Ranbaxy Laboratories Ltd, Pharmaceutical Division, and is widely recognized in the Industry for some of the most successful product launches within India. Beginning in 1996, he worked in assignments at corporate headquarters in Indianapolis in business development, intercontinental strategy, and human resources before returning to India in 1999, as CEO. This broad-based knowledge of both the cross-functional, and cross-cultural aspects of the industry has served Gulati well throughout his career. In India, Gulati has served as Chairman of the Pharmaceutical Council of the Indo American Chambers of Commerce, Vice President of the Organization of Pharmaceutical Producers of India, and was on the advisory board of the National Institute of Pharmaceutical Education and Research, as well as Narsee Monjee Institute of Management. Ming Guo, Vice President, Pharmaceutical Science and Manufacturing, Ascenta Therapeutics, Inc. Dr. Guo has joined Ascenta Therapeutics in March 2005. He has assumed the responsibilities of Vice President of Pharmaceutical Sciences and Manufacturing. He came to Ascenta from Pfizer, where, for eight years, he led many aspects of drug development activities, both in-house and outsourced, for multiple clinical drug development candidates in oncology, metabolic diseases, and infectious diseases (anti-viral agents). In addition to his technical leadership in process chemistry and manufacturing at Pfizer, Dr. Guo was also responsible for project management of exploratory drug candidates focusing on CMC issues. Prior to Pfizer, Dr. Guo was responsible for process chemistry research and development of pharmaceuticals and agrichemicals at Monsanto and ABC Laboratories for seven years. Before his industrial career started at the beginning of 1991, Dr. Guo was an organic chemistry research associate at the University of California at San Diego (UCSD) and the Institute of Materia Medica (IMM) in China. He holds a Ph.D. in Organic Chemistry from UCSD and an M.S. in Medicinal Chemistry from IMM. Dr. Guo is a co-founder of SABPA (www.sabpa.org), a southern California non-profit professional organization, and the first Chairman of the Board of Directors from its inauguration on 8 June 2002 until June 2005. Matthew Levy, Director, Protein & Small Molecule Division, Applied Biosystems – China Matt currently holds a position as the Director for the Proteomics and Small Molecule business unit at Applied Biosystems in China. In this position, he is responsible for developing the mass spec business inside China. Prior to this role, he was the Director of Market Development focused on the pharmaceutical segment and was responsible for developing and executing a marketing and sales strategy to increase revenue within this segment. He joined Applied Biosystems after several successful years with the IBM Life Sciences group. 　Within this group, his primary role was to manage partnerships with bioinformatics companies to develop new information technology solutions in an effort to improve the process for drug discovery. During his time at IBM, Matt was also part of the IBM Global Medical Imaging team. As a result, Matt thoroughly understands the value of combining biological, clinical and technical information to provide personalized medicine to improve treatment. He is leveraging this experience to develop new solutions targeted towards greater R&D efficiency in the life sciences industry. Matt has a BS (Marketing) and MS (Computer Information Systems/Quant Bus Methods) from California State (East Bay), as well as an MBA from Carnegie Mellon University. Zili Li, M.D., Ph.D., , Clinical Research Operations- Asia Pacific, Merck & Co., Inc., former Medical Team Leader of US FDA Dr. Li is a licensed and board-certified physician in the US. He joined Merck & Co., Inc., in June 2005, as a Director of Clinical Research Operations – Asia Pacific, and currently is on a special assignment in Beijing China, leading regulatory policy development effort in building a new model to interact with the agency professionally at a policy level. In the past two years, Dr. Li has been working closely with Chinese SFDA and its review centers in promoting science-based decision-making principles, and has gained a special recognition by the agency. Prior to joining Merck, Dr. Li had worked at US FDA for seven years in various regulatory/clinical capacities with increasing responsibilities. As a medical team leader with the office of new drugs under FDA/CDER, Dr. Li oversaw the clinical and regulatory review of IND and NDA applications for the new drug products. He was responsible for making a final recommendation on a clinical hold decision for IND clinical protocols, and on the approvability of the pending NDA applications. In addition, Dr. Li participated in the development of FDA’s guidance to industry and presented at FDA’s advisory committee meeting. Dr. Li is an expert on the regulatory and scientific issues related to the efficacy and safety assessment of the new drug products, and he was a recipient of many FDA awards, including 2003 FDA Scientific Achievement Award. Michael N. Liebman, Ph.D., Executive Director, Windber Research Institute Michael N. Liebman, Ph.D. is executive Director of the Windber Research Institute after serving as Chief Scientific Officer since November, 2003. Prior, he was Director, Computational Biology and Biomedical Informatics at the Abramson Family Cancer Research Institute of the University of Pennsylvania Cancer Center since September, 2000. He previously was Global Head of Computational Genomics at Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals. He was also Director of Genomics for Vysis, Inc and Director of Bioinformatics at the Amoco Technology Company. He has served on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Bipohysics. He serves on 12 international scientific advisory boards consults for 5 pharma/biotech companies and has been on the economic development programs in the Philadelphia Life Sciences Sector and the State of Illinois Biotechnology Commission. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and is currently Chair of the Healthcare Task Force for the SMART program, and on the Human Health and Medicinal Chemistry Commission of the IUPAC. His research focuses on computational models of disease progression stressing risk detection, disease process modeling and analysis of lifestyle interactions. Mao Mao, M.D., Ph.D., Associate Director/China Project Liaison, Oncology Clinical Research, Merck Research Laboratories Mao Mao is Associate Director of Oncology Research Clinical, Merck Research Laboratories, Merck & Co., Inc. Currently he is working on biomarker discovery and coordinating extensive collaborations with academic institutions to promote personalized cancer therapy in Asia Pacific region. As one of the founding members of the National Human Genome Center at Shanghai, he established the first high-throughput DNA sequencing facility and pioneered genome research in China. Eric Meyers, Vice President, Global Initiatives, Cambridge Healthtech Associates Eric Meyers leads Cambridge Healthtech Associates’ (CHA) multi-company, collaborative projects focused on pharma R&D productivity improvement opportunities in China and India. In a recently completed project, Mr. Meyers led a team including senior representatives from seven of the top 20 pharma to explore the potential of conducting pre-clinical safety studies in China. Included in this study was a review of 42 labs with site visits by the project team to over a dozen of the leading labs. Mr. Meyers has also authored a number of strategic industry reports covering the globalization of drug development to emerging countries. Mr. Meyers joined CHA from 3rd Millennium, Inc., a leading informatics consultancy to the biopharmaceutical industry. As Chief Operating Officer from 2000 to 2005, he helped the company achieve market leadership, successful service line extensions, and sustained profitability. Prior to 3rd Millennium, Eric was Vice President of Marketing and Sales at HealthShare Technology, a venture-backed healthcare software company acquired by WebMD. Prior to HealthShare Technology, Eric spent seven years at Hewlett-Packard where he held various management positions in operations, product management, and market development of its medical products business unit. Eric Meyers received both an MBA and a BA from Harvard University. Lorenz Ng, M.D ., CEO and Managing Partner, Global Ng Associates, LLC and former Vice President, Research & Alliance & Business Development, Asia Pacific, Eli Lilly & Co (Asia) Ng earned his B.A. from Stanford University in 1961 and M.D. from Columbia University in 1965. Board certified in Neurology , he spent 12 years at the NIH. Ng left government service to enter private practice of medicine. In 1986, he established the Washington Pain and Rehabilitation Center, Inc. Ng received the S. Weir Mitchell Award from the American Academy of Neurology in 1971, the A.E. Bennett Award in Biological Psychiatry in 1972 and the Commendation Medal of the U.S. Public Health Service in 1981. Ng served as consultant to Dr. Gus Watanabe, Executive V.P. for R&D, Eli Lilly, from 1996-97 and was instrumental in the establishment of the Lilly-NUS Clinical Pharmacology Center in Singapore, Lilly’s first R&D center in Asia. In 1998, he was recruited to be Lilly Medical and Regulatory Affairs Director for Greater China based in Shanghai. In 2001, he started a collaboration with the Wu Jieping Foundation and the Chinese Medical Association (CMA) which led to the development of the CMA-Lilly.com website for the promotion of distance learning among doctors. In 2002, he assumed his current position as Vice President and Group Director,Research Alliances and Business Development for Asia. During this period, he led an initiative which resulted in creation of Lilly’s research facilities in chemistry and preclinical toxicology in the Zhangjiang Hi-Tech Park in Pudong, Shanghai. These two facilities are the largest of their kind in China among multinational pharma companies and has grown from 12 employees four years ago to about 300 employees today. Its business model has been widely cited as an example of an innovative partnership between a multinational pharma and a Chinese partner. Helen Niu, M.D., Ph.D., Director, Global Development Operations, Asia & Latin America, Amgen, Inc. Speaker bio to be submitted. Suresh Poosala DVM, Ph.D., Chief of Comparative Medicine and Animal Program Director, NIH Dr. Poosala is a veterinary pathologist from Iowa State University and lab animal residency trained at University of Maryland. He has been serving in the roles of Lab Animal Program Director and Chief of Comparative Medicine at NIA along with several other additional responsibilities. He is an active participant in meetings regarding animal welfare, regulations and is an ad hoc site visitor with AAALAC. He is now actively involved in the conceptualizing, design and commissioning of a state-of-the-art brand new vivarium. During his association with Pathology and Lab animal facility management for the last 12 years, he has gained immense experience in this emerging field. Chris Song, Manager, Pharmaceutical Segment, Applied Biosystems, former Special Project Manager, AstraZeneca R&D, China Chris currently holds a position as the Manager for Pharmaceutical Segment at Applied Biosystems (AB) in China. In his position, he is responsible for developing both the mass spec, and molecular and cellular biology business in pharmaceutical/biotech industry in China. Prior to joining AB, he worked as Special Project Manager with AstraZeneca R&D Department China. Within this group, his primary role was to manage partnerships with SFDA, academic research institutes, pharmaceutical/biotech companies, and to assess opportunities for outsourcing. During his time at AstraZeneca, Chris was also part of the team to evaluate possibility of setting up R&D Center in China.  Prior to that, he holds a position as the Business Development Manager for Oncology Business Unit at Novartis China. His major role is to develop strategic plan for the Unit, and to identify and assess in-licensing oncology candidates with great potential for fast growing China market and other regions. Chris was a medical researcher at leading academic institutes for more than 10years in USA and Australia before moving to business. Whaijen Soo, M.D., Ph.D., Senior Vice President, Medical Research, Biogen Idec As Senior Vice President of Medical Research at Biogen Idec, Inc, Dr. Soo has been responsible for the worldwide clinical development of all drugs in the Biogen Idec portfolio. Prior to joining Biogen in December 2002, Dr. Soo spent eighteen years with Hoffmann La-Roche Inc., as head of clinical sciences in charge of worldwide clinical development of new anticancer drugs, antiviral and immunotherapies against AIDS and other viral diseases, as well as drugs used for transplantation. Dr. Soo received a Ph.D. in Biochemistry from the University of California, Berkeley. He also has an M.D. from the University of California, San Francisco and received postgraduate training at Brigham and Women’s Hospital in Boston. Edmund Tsuei, Ph.D., Regional Head, Pharma Development Operations, Asia-Pacific-Africa, Roche Products Pty Limited Dr Edmund Tsuei received his undergraduate degree in the United States of America and his doctorate from the University of Sydney in 1980. Based in Sydney, Australia, Ed has been working in the area of global drug development, conducting high quality clinical trials, in the Asia-Pacific region since the mid 1980s. He has built up regional global drug development organizations in Asia-Pacific first for Parke-Davis, then for Searle before joining Roche. He is currently Regional Head of Pharma Development Operations, Asia-Pacific-Africa at Roche Products Pty Limited, responsible for global drug development activities in the region. He is a frequent speaker in international conferences on drug development in Asia. In addition to global drug development, Ed’s personal research interest is in the areas of both theoretical and clinical pharmacokinetics and has published many papers in this area. Steve Q. Yang, Ph.D., Head of Research, Asia, Pfizer Global Research & Development Dr. Steve Yang is Head of Research, Asia for Pfizer Global Research & Development. He is based in Shanghai, China. His key responsibilities include exploring R&D capabilities of Asia countries (especially in research related scientific disciplines), establishing and managing partnerships with biotech companies, academic research institutions, and R&D service providers, and developing longer term Asia R&D investment strategy for Pfizer. Prior to his current role, he was an Executive Director and the global head of Strategic Management Group of Pfizer Global Research and Development. His main responsibilities included providing strategic advice and consulting service to the senior executives of the Pfizer R&D organization and managing a global team of internal consultants. He has extensive experience in business and corporate development, strategic planning, portfolio management, and merger and acquisition. Since he joined Pfizer, Dr. Yang led a series of high impact projects in the areas of R&D strategy, post merger integration, and R&D productivity improvements. He received a Pfizer Global Research and Development Achievement Award in 2003. In 2004, Dr. Yang joins two global leadership teams in Pfizer R&D: World Wide Discovery and Research Technology. In 2005, he joins Pfizer s Research Leadership Team. In 2006, he expanded the scope of his work to support senior leaders at Pfizer's Worldwide Development organization. Hua Zheng, M.D., Ph.D., DABT., RAC, Director, Global Regulatory Affairs, Tibotec, Inc. (J&J) Dr. Zheng has more than 10 years experience in regulatory science and drug development. Dr. Zheng developed his career in regulatory affairs, clinical development and preclinical safety evaluation. Since 2001, Dr. Zheng works at J&J as a Director in Global Regulatory Affairs and Global Regulatory Leader. In this role, Dr. Zheng has worked on several late phase oncology and anti-HIV products and has led global clinical trial applications, IND and NDA submission activities, regulatory interactions with health authorities, including Chinese SFDA. He currently works at Tibotec, Inc., a Johnson & Johnson Pharma R&D Company specializing development and commercialization of innovative anti-viral products. Prior to J&J, Dr. Zheng worked at Pfizer (PGRD) as an US Regulatory Leader. Before industry career, he was a PharmTox Reviewer at CDER FDA. Dr. Zheng also has over 7 years research experience at multiple academic institutions. Dr. Zheng had his medical and postgraduate (MS in Pathology) training at the former Beijing Medical University (BMU) and his PhD training in Toxicology at UC Irvine.  Guoxin Zhu, Ph.D., CSO / Head of China Chemistry, Discovery Chemistry Research & Technology, Eli Lilly Asia, Inc. Shanghai Rep. Office Dr. Zhu was expatriated to Shanghai in 2005 and appointed as Head of Discovery Chemistry Research of Eli Lilly in China. Dr. Zhu earned his bachelor degree from Hangzhou University in 1990 and doctorate in organic chemistry from Shanghai Institute of Organic Chemistry, the Chinese Academy of Science in 1995. He joined the Lilly Research Laboratories in 1998 and quickly developed into a successful drug hunter. He has personally contributed to multiple successful projects in metabolic diseases and oncology. In his administrative role, he is responsible for the development of research strategy and drug discovery process and management of the drug discovery programs in China. Dr. Zhu has worked to develop and integrate the resources in China into a highly effective extension of global capability of Discovery Chemistry Research and Technology division. Additionally, he has aided in positioning Lilly to capitalize on the evolving landscape of scientific possibilities in Asia. Most recently, Dr. Zhu is promoted to the position of Director, Discovery Chemistry Research & Technology in Lilly. In this role, he is responsible for the endocrine chemistry portfolio and developing Lilly Research Laboratories’ lead generation strategy